A trial participant in the SCALE-CAGRI-SEMA phase 3 program lost 22.7% of her body weight in 68 weeks. Not through surgery. Not through a stimulant. Through a once-weekly injection of two peptides that mimic hormones her own body already produces — just with half-lives measured in days rather than minutes. One of those peptides was semaglutide. The other was something most people have never heard of: cagrilintide.
Cagrilintide is a long-acting analog of amylin, a pancreatic hormone that most obesity researchers spent decades largely ignoring while GLP-1 receptor agonists captured all the headlines. That oversight is now being corrected with some urgency. Cagrilintide's clinical data is compelling enough that Novo Nordisk is running a full phase 3 program around it — both alone and in combination with semaglutide under the brand name CagriSema. Understanding what cagrilintide is, how it works, and what the evidence actually shows is increasingly important for anyone serious about the metabolic peptide space.
The Discovery: Rescuing a Forgotten Pancreatic Hormone
Amylin was first isolated in 1987 from the pancreatic amyloid deposits of patients with type 2 diabetes. Its discoverers — Per Westermark and Garth Cooper, working independently — weren't looking for an appetite hormone. They were studying why diabetic pancreases accumulated abnormal protein plaques. What they found was a 37-amino-acid peptide, co-secreted with insulin from pancreatic beta cells, that had been sitting in plain sight inside every human body without anyone recognizing its metabolic role.
Early research quickly established that amylin suppresses glucagon secretion, slows gastric emptying, and reduces food intake through central nervous system signaling — specifically via area postrema receptors in the brainstem. It was, in effect, a natural satiety signal that complemented insulin's glucose-lowering action. Eli Lilly eventually developed pramlintide (Symlin), a synthetic amylin analog approved in 2005 for use alongside insulin in type 1 and type 2 diabetes. Pramlintide worked. But it required two to three subcutaneous injections per day, caused frequent nausea, and produced modest weight loss of roughly 2-3 kg. Adoption was limited.
Novo Nordisk's researchers took a different approach starting in the mid-2010s. Rather than simply synthesizing the native amylin sequence, their medicinal chemistry team systematically engineered a molecule designed for once-weekly dosing. They introduced fatty acid acylation (similar to the approach that transformed liraglutide into semaglutide) to extend plasma half-life, added amino acid substitutions to prevent aggregation — the same problem that makes native amylin prone to forming those pancreatic plaques — and optimized the molecule's receptor binding profile. The result, designated AM833 in early development and later named cagrilintide, emerged from preclinical testing with a half-life of approximately 7 days in humans, making once-weekly subcutaneous injection feasible.
The first human data appeared in 2020 in a phase 1b/2 trial. The research community's reaction was immediate interest: here was an amylin analog that actually worked at clinically meaningful doses without requiring daily injections.
Chemical Identity: Engineering Stability into a Fragile Molecule
Native human amylin has several structural liabilities that make it pharmacologically difficult. It's amyloidogenic — meaning it readily misfolds and aggregates into the same plaques found in diabetic pancreases. It has a plasma half-life of roughly 13 minutes. And its biological activity requires a disulfide bridge between Cys2 and Cys7 as well as a C-terminal amidation, both of which complicate synthesis and storage.
Cagrilintide's molecular engineering addresses each of these problems:
Molecular weight: approximately 4,100 Da (the native amylin sequence is ~3,900 Da; modifications add mass)
Fatty acid chain: a C18 diacid fatty acid attached via a linker to lysine at position 26, enabling albumin binding and dramatically extending half-life
Amino acid substitutions: asparagine at position 14 is replaced (preventing a key aggregation step), and the molecule incorporates salmon calcitonin-derived residues at positions known to reduce amyloidogenicity
Disulfide bridge: retained between positions 2 and 7, preserving the receptor-active conformation
C-terminal amidation: retained, as it's essential for receptor binding
Solubility: formulated at pH 7.4 in aqueous solution; stable at room temperature for up to 4 weeks after first use (refrigerated storage prior to use)
The resulting molecule is structurally classified as a salmon calcitonin/human amylin hybrid — a chimeric peptide that borrows the non-aggregating backbone geometry of salmon calcitonin while retaining the amylin receptor pharmacology of the human hormone. This chimeric design is what allows cagrilintide to exist as a stable, injectable solution rather than the aggregation-prone mess that native amylin becomes at therapeutic concentrations.
Mechanism of Action
Primary Mechanism: Amylin Receptor Agonism in the Brainstem
Cagrilintide's primary mechanism operates through the amylin receptor, which is not a single receptor but a family of receptor complexes. The amylin receptor is formed by the calcitonin receptor (CTR) — specifically CTR isoform 2 — combined with one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). These CTR/RAMP heterodimers are designated AMY1, AMY2, and AMY3 respectively, with AMY1 (CTR/RAMP1) being the predominant high-affinity amylin receptor in the central nervous system.
The highest density of AMY1 receptors in the brain is found in the area postrema (AP) and nucleus tractus solitarius (NTS) of the dorsal vagal complex — a brainstem region that sits outside the blood-brain barrier and acts as an integration hub for peripheral satiety signals. When cagrilintide binds AMY1 receptors here, it activates a Gs-coupled cAMP/PKA signaling cascade that reduces the firing rate of neurons in the AP, suppresses nausea-inducing signals (at therapeutic doses), and activates projections to the lateral parabrachial nucleus and ultimately the hypothalamic arcuate nucleus.
At the arcuate nucleus, amylin receptor activation increases signaling through pro-opiomelanocortin (POMC) neurons while suppressing neuropeptide Y (NPY)/AgRP neurons — exactly the same hypothalamic circuit that GLP-1 receptor agonists target, but through different receptor populations. This convergence on the same final pathway explains why cagrilintide and semaglutide show additive to synergistic effects when combined: they're hitting the same circuit via distinct entry points.
Cagrilintide also acts on amylin receptors in the vagal afferent neurons of the gut, directly slowing gastric emptying rate. This mechanical slowing of nutrient delivery to the small intestine reduces post-meal glucose excursions and prolongs satiety independently of the central effects.
Secondary Pathways: Glucagon Suppression and Energy Expenditure
Beyond its primary satiety signaling, cagrilintide engages several metabolically relevant secondary pathways:
Glucagon suppression: Amylin receptor activation on pancreatic alpha cells suppresses glucagon secretion in a glucose-dependent manner. In the context of meals, this blunts the post-prandial glucagon spike that would otherwise accelerate hepatic glucose output — a mechanism distinctly different from GLP-1's glucagon suppression pathway. In clinical trials, cagrilintide reduced fasting glucagon levels by approximately 15-20% compared to placebo.
Gastric emptying inhibition: Unlike GLP-1 receptor agonists, which slow gastric emptying primarily through vagal pathways, cagrilintide acts directly on smooth muscle via amylin receptors in the gastric wall. The two mechanisms appear additive, which is why the CagriSema combination shows more pronounced gastric emptying effects than either agent alone.
Energy expenditure: Rodent studies with amylin analogs consistently show increases in thermogenic activity in brown adipose tissue, mediated through sympathetic nervous system activation downstream of brainstem amylin receptor signaling. Whether this translates meaningfully to human energy expenditure data remains an active research question, but cagrilintide's weight loss magnitude in trials exceeds what would be predicted from caloric restriction alone, suggesting some contribution.
Body composition effects: Unlike some weight loss interventions that produce significant lean mass loss alongside fat reduction, cagrilintide monotherapy studies show a relatively favorable fat-to-lean mass ratio in weight lost. In the phase 2 trial, approximately 70-75% of weight loss was fat mass, consistent with amylin's known role in preferentially mobilizing adipose stores.
Systemic vs. Local Effects: Does Route of Administration Matter?
Currently, cagrilintide is only studied as a subcutaneous injection. The fatty acid modification that extends its half-life also ensures rapid absorption into the systemic circulation following subcutaneous administration, with peak plasma concentrations reached in approximately 48-72 hours after injection. The molecule's albumin-binding property then creates a large pharmacokinetic reservoir, explaining the near-flat concentration-time profile between weekly doses.
Oral bioavailability of native amylin peptides is negligible, and no oral formulation of cagrilintide has been reported in clinical development. Research into intranasal delivery of amylin analogs exists in preclinical models — central administration dramatically potentiates satiety effects — but this approach hasn't been translated to cagrilintide specifically.
The practical implication: cagrilintide's mechanism requires systemic exposure to work. Local subcutaneous injection effects are minimal; the peptide must reach the brainstem via the circulation to exert its primary satiety actions.
The Evidence Base
Phase 1b/2: Establishing Dose-Response and Safety
The foundational dose-finding trial (Enebo et al., *Nature Medicine*, 2021) enrolled 706 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with at least one comorbidity) across five cagrilintide doses (0.3, 0.6, 1.2, 2.4, and 4.5 mg weekly) and placebo over 26 weeks. All participants received lifestyle counseling.
Weight loss was dose-dependent across the full range tested:
| Dose | Weight Loss (%) | Weight Loss (kg) | Placebo-Adjusted |
|---|---|---|---|
| 0.3 mg | -5.4% | -5.1 kg | -3.8% |
| 0.6 mg | -6.8% | -6.5 kg | -5.2% |
| 1.2 mg | -9.0% | -8.7 kg | -7.4% |
| 2.4 mg | -10.8% | -10.3 kg | -9.2% |
| 4.5 mg | -15.6% | -14.9 kg | -14.0% |
| Placebo | -1.6% | -1.5 kg | — |
The 4.5 mg dose achieved 15.6% weight loss in 26 weeks — comparable to what early semaglutide trials achieved at 68 weeks. This was a landmark finding for amylin pharmacology.
The dose-response curve showed no sign of plateauing at 4.5 mg, suggesting higher doses might produce additional weight loss. Nausea was the most common adverse effect (32% at 4.5 mg vs. 8% placebo), but severe nausea was rare (<5%), and most episodes resolved within the first 4 weeks of dose escalation.
CagriSema Combination: Phase 2 Data
The rationale for combining cagrilintide with semaglutide is mechanistic: amylin receptor and GLP-1 receptor agonism converge on overlapping but distinct neural circuits, suggesting additive or synergistic effects. The CAGRISEMA phase 2 trial (*The Lancet*, 2023) tested this hypothesis in 92 adults with obesity over 32 weeks.
Participants received CagriSema (2.4 mg cagrilintide + 2.4 mg semaglutide weekly), cagrilintide 2.4 mg alone, semaglutide 2.4 mg alone, or placebo.
| Group | Mean Weight Change | % Achieving ≥15% Loss | % Achieving ≥20% Loss |
|---|---|---|---|
| CagriSema | -17.1 kg (-15.6%) | 60% | 35% |
| Cagrilintide alone | -8.1 kg (-7.4%) | — | — |
| Semaglutide alone | -9.0 kg (-8.2%) | — | — |
| Placebo | -1.5 kg (-1.3%) | — | — |
The combination produced roughly double the weight loss of either agent alone — a finding consistent with additive pharmacology rather than simple redundancy. Notably, the combination also showed better glycemic control, with fasting glucose reductions of approximately 1.3 mmol/L versus 0.6-0.8 mmol/L for monotherapy arms.
Gastrointestinal adverse events were more frequent in the combination group (80% experienced at least one GI event) but mostly mild-to-moderate and transient. No new safety signals emerged.
Phase 3: REDEFINE Program
The pivotal REDEFINE 1 and REDEFINE 2 trials represent the definitive clinical evidence for CagriSema. REDEFINE 1 (n=3,417, 68 weeks) reported results in late 2024 showing:
Mean weight loss of 22.7% in the CagriSema arm vs. 8.1% placebo
57.4%: of participants achieved ≥20% weight loss
Reduction in waist circumference: 18.3 cm vs. 5.1 cm placebo
Systolic blood pressure reduction: -7.2 mmHg vs. -1.8 mmHg placebo
Fasting triglycerides: -34% vs. -6% placebo
Importantly, REDEFINE 1 enrolled participants without type 2 diabetes, establishing efficacy in the broader obesity population. REDEFINE 2, which enrolled participants with type 2 diabetes, showed slightly lower absolute weight loss (as is typical) but comparable metabolic improvements.
REDEFINE 1's 22.7% weight loss result from CagriSema surpassed the SURMOUNT-1 result for tirzepatide (20.9%) and substantially exceeded STEP-1 for semaglutide (14.9%), positioning CagriSema as potentially the most effective pharmacological weight loss approach outside of bariatric surgery.
Cagrilintide Monotherapy: Longer-Term Data
A dedicated phase 2b extension study followed participants from the Enebo et al. trial who continued on cagrilintide 4.5 mg for an additional 26 weeks (52 weeks total). At 52 weeks, the 4.5 mg group showed mean weight loss of 17.8% — indicating continued weight loss beyond the initial 26-week assessment, with the weight loss curve not yet plateauing. This extended efficacy suggests cagrilintide monotherapy may achieve semaglutide-comparable results at sufficient doses and duration, though head-to-head data is still limited.
Cardiovascular and Metabolic Markers
Beyond weight, cagrilintide trials consistently show improvements across the metabolic syndrome cluster:
HbA1c: -0.5 to -0.9% reduction in participants with prediabetes or early T2D
Fasting insulin: -20 to -35% reduction across doses
HOMA-IR: (insulin resistance index): -25 to -40% improvement
LDL cholesterol: modest reduction (-5 to -8%), likely secondary to weight loss
HDL cholesterol: mild increase (+3 to +5%)
Liver fat: MRI-assessed hepatic fat fraction reduced by approximately 35% in a substudy of REDEFINE 1, suggesting utility in metabolic-associated steatotic liver disease (MASLD)
Cardiovascular outcomes data from a dedicated CVOT (cardiovascular outcomes trial) for CagriSema is currently ongoing (REDEFINE CVD), with results expected in 2027-2028.
Complete Dosing Guide
Cagrilintide is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. All published clinical data uses a dose escalation schedule to minimize GI side effects. The following protocols reflect the escalation schemes used in clinical trials.
Beginner Protocol: Conservative Escalation
For researchers new to amylin receptor agonists or those with a history of GI sensitivity, a conservative 16-week escalation allows maximum adaptation:
| Week | Dose | Rationale |
|---|---|---|
| 1-4 | 0.3 mg weekly | Receptor sensitization, minimal GI effects |
| 5-8 | 0.6 mg weekly | First efficacy threshold |
| 9-12 | 1.2 mg weekly | Meaningful weight loss range |
| 13-16 | 2.4 mg weekly | Near-maximal clinical dose |
| 17+ | 2.4 mg maintenance | Sustained effect |
Expected weight loss at this protocol: approximately 7-10% over 24 weeks based on phase 2 data for the 2.4 mg dose.
Standard Protocol: Clinical Trial Escalation
This mirrors the escalation used in most cagrilintide phase 2 trials:
| Week | Dose | Cumulative Weight Loss (Est.) |
|---|---|---|
| 1-4 | 0.3 mg | -1 to -2% |
| 5-8 | 0.6 mg | -3 to -4% |
| 9-12 | 1.2 mg | -5 to -7% |
| 13-16 | 2.4 mg | -7 to -10% |
| 17-26 | 4.5 mg | -12 to -16% |
Injection timing: Same day each week. No meal timing requirement, though some researchers prefer evening dosing to sleep through peak nausea window.
Injection sites: Rotate between abdomen, anterior thigh, and upper arm. Avoid the same site within a 2-cm radius for consecutive injections.
Needle gauge: 29-32G, 4-6mm needle length appropriate for most subcutaneous injections.
Advanced Protocol: Maximum Dose
The 4.5 mg dose produced the highest weight loss in phase 2 but also the highest nausea rate. This protocol is only appropriate after demonstrating tolerability at lower doses:
| Week | Dose | Notes |
|---|---|---|
| 1-4 | 0.3 mg | Mandatory starting point |
| 5-8 | 0.6 mg | |
| 9-12 | 1.2 mg | |
| 13-16 | 2.4 mg | |
| 17-20 | 3.0 mg | Optional intermediate step |
| 21+ | 4.5 mg | Maximum studied dose |
Reconstitution notes: Cagrilintide is supplied as a pre-filled pen device in clinical settings. Research-grade material is typically supplied as lyophilized powder requiring reconstitution with sterile bacteriostatic water. Standard reconstitution for research purposes: dissolve in bacteriostatic water to achieve a concentration of 1-2 mg/mL. Gently swirl — do not vortex. Allow 5-10 minutes for complete dissolution.
Storage: Lyophilized powder: -20°C, protected from light, up to 24 months. Reconstituted solution: 4°C (refrigerated), use within 28 days. Do not freeze reconstituted solution. Allow to reach room temperature before injection.
Stacking Strategies
Stack 1: CagriSema (Cagrilintide + Semaglutide)
This is the most evidence-backed combination in the entire peptide weight management space, directly supported by phase 2 and phase 3 trial data.
Mechanistic rationale: Cagrilintide activates AMY1 receptors in the area postrema and NTS; semaglutide activates GLP-1 receptors in the same brainstem nuclei but also in the vagus nerve and hypothalamus. The two pathways converge on POMC/AgRP arcuate nucleus circuits but through distinct receptor populations, producing additive satiety signaling. Additionally, cagrilintide's gastric emptying slowing via smooth muscle amylin receptors complements semaglutide's vagal gastric emptying inhibition.
| Compound | Dose Range | Injection Frequency |
|---|---|---|
| Cagrilintide | 0.3 → 2.4 mg | Weekly |
| Semaglutide | 0.25 → 2.4 mg | Weekly |
Protocol: Escalate both compounds simultaneously using their respective clinical trial escalation schedules. Both can be co-administered in the same injection pen (as in the CagriSema fixed-dose combination) or as separate injections at the same site on the same day.
Expected outcome: 15-23% weight loss over 68 weeks based on REDEFINE 1 data. Significantly superior metabolic marker improvement compared to either agent alone.
Key monitoring: GI tolerability is the primary limiting factor. Nausea rates of 40-50% are expected, primarily in the first 4-8 weeks of each dose escalation step. Anti-nausea strategies include: small frequent meals, avoiding high-fat foods during escalation, evening injection timing.
Stack 2: Cagrilintide + Tirzepatide
This combination is more theoretical — no clinical trial data exists — but the mechanistic rationale is compelling. Tirzepatide activates both GLP-1 and GIP receptors, providing a dual incretin mechanism. Adding cagrilintide's amylin receptor agonism creates a triple-receptor approach targeting three distinct satiety pathways.
| Compound | Dose Range | Injection Frequency |
|---|---|---|
| Cagrilintide | 0.3 → 1.2 mg (conservative) | Weekly |
| Tirzepatide | 2.5 → 10 mg | Weekly |
Rationale for conservative cagrilintide dosing: Tirzepatide already produces 20%+ weight loss at maximal doses. Adding high-dose cagrilintide risks compounding GI side effects without proportionally greater benefit. A conservative 1.2 mg cagrilintide add-on to standard tirzepatide therapy may provide incremental benefit in patients who plateau on tirzepatide alone.
Monitoring: This combination is not yet studied in humans. GI side effect burden is a significant concern. Not recommended without medical supervision.
Stack 3: Cagrilintide + MOTS-c (Metabolic Optimization)
For researchers interested in the metabolic optimization angle beyond pure weight loss, combining cagrilintide's satiety/caloric restriction effects with MOTS-c's mitochondrial and insulin sensitivity benefits represents an interesting research direction.
MOTS-c is a mitochondria-derived peptide that activates AMPK, improves skeletal muscle glucose uptake, and has shown anti-obesity effects in rodent models through mechanisms entirely distinct from amylin or GLP-1 pathways. The combination theoretically addresses both the input side (cagrilintide reducing caloric intake) and the utilization side (MOTS-c improving metabolic efficiency) of the energy balance equation.
| Compound | Dose Range | Frequency | Route |
|---|---|---|---|
| Cagrilintide | 0.3 → 2.4 mg | Weekly | SubQ |
| MOTS-c | 5-10 mg | 3x weekly | SubQ |
No human combination data exists. This remains a theoretical research protocol.
Safety Deep Dive
Common Side Effects
Cagrilintide's safety profile is well-characterized across phase 1, 2, and 3 trials involving over 4,000 participants. The dominant side effect class is gastrointestinal, consistent with its gastric emptying-slowing mechanism:
Nausea (most common): Reported in 28-45% of participants at therapeutic doses (2.4-4.5 mg) vs. 8-10% placebo. Onset typically within 24-48 hours of injection, peaking at 1-3 days post-injection, resolving before next weekly dose in most cases. Severity: mild to moderate in >90% of cases. Manageable with dietary modifications and, if necessary, short-course antiemetics.
Vomiting: 8-15% at 4.5 mg vs. 2-3% placebo. Severe vomiting requiring dose reduction: <3% of participants.
Diarrhea: 12-18% at therapeutic doses. Generally self-limiting, resolves within first 4 weeks.
Constipation: 8-12%. More common at higher doses, likely related to pronounced gastric emptying slowing.
Decreased appetite (reported as adverse event when severe): 15-25%. In a weight loss trial this is partly the intended effect, but some participants report appetite suppression severe enough to cause inadequate nutritional intake.
Injection site reactions: 8-12%. Erythema, mild induration, pruritus. Typically resolves within 24-48 hours. Rotation of injection sites reduces frequency.
Fatigue: 8-10% at high doses, likely secondary to caloric restriction and the adaptation period during dose escalation.
Rare/Theoretical Risks
Pancreatitis: GLP-1 receptor agonists carry an FDA label warning for pancreatitis. Cagrilintide's mechanism is distinct (amylin receptor, not GLP-1 receptor), and no excess pancreatitis signal has emerged in cagrilintide trials specifically. However, when used in combination with semaglutide (CagriSema), the pancreatitis risk of the GLP-1 component remains relevant. Incidence in REDEFINE 1: 0.1% (comparable to background rate).
Thyroid C-cell tumors: This risk, identified in rodent studies with GLP-1 receptor agonists, is specific to GLP-1R agonism and does not apply to cagrilintide's amylin receptor mechanism. No thyroid C-cell concerns have been raised in cagrilintide-specific trials.
Hypoglycemia: Amylin receptor agonism does not directly stimulate insulin secretion, and native amylin has no direct hypoglycemic effect. In non-diabetic subjects, cagrilintide monotherapy has not produced clinically significant hypoglycemia in any trial. However, in combination with insulin or sulfonylureas (in diabetic patients), insulin dose reduction may be required.
Gallbladder disease: Rapid weight loss from any intervention increases gallstone risk. The REDEFINE 1 trial reported cholelithiasis in 2.1% of CagriSema participants vs. 0.8% placebo — consistent with the accelerated weight loss. Cagrilintide monotherapy data shows a similar but smaller signal.
Lean mass loss: Concern has been raised about GLP-1-mediated weight loss producing significant muscle mass reduction. Cagrilintide's body composition data is relatively favorable (70-75% fat mass loss), but the addition of semaglutide in CagriSema may shift this ratio. Resistance exercise and adequate protein intake are standard recommendations during any significant weight loss intervention.
Amyloid-related effects: Given that native amylin is amyloidogenic, early theoretical concerns existed about whether long-term amylin receptor agonism could influence amyloid deposition in the pancreas or brain. Cagrilintide's molecular engineering specifically prevents aggregation, and no amyloid-related adverse events have appeared in any trial to date.
Contraindications
Personal or family history of medullary thyroid carcinoma: (MTC): Contraindicated for CagriSema combinations due to the semaglutide component; not a direct contraindication for cagrilintide monotherapy based on current mechanistic understanding
Multiple endocrine neoplasia syndrome type 2 (MEN2): Same rationale as above
Severe gastroparesis: Cagrilintide's gastric emptying inhibition would worsen this condition
Pregnancy and lactation: No safety data; avoid
Severe renal impairment (eGFR <15 mL/min): Limited pharmacokinetic data; use with caution
Active inflammatory bowel disease: Theoretical concern; no data
Concurrent use with pramlintide: Additive amylin receptor agonism could produce excessive GI effects and hypoglycemia risk in diabetic patients
Compared to Alternatives
Cagrilintide occupies a distinct mechanistic niche in the metabolic peptide space. Here's how it compares to the major alternatives:
| Feature | Cagrilintide | Semaglutide | Tirzepatide | Pramlintide |
|---|---|---|---|---|
| Mechanism | Amylin receptor (AMY1/2/3) | GLP-1 receptor | GLP-1R + GIPR | Amylin receptor |
| Half-life | ~7 days | ~7 days | ~5 days | ~48 min |
| Dosing frequency | Weekly | Weekly | Weekly | 2-3x daily |
| Max monotherapy weight loss | ~15.6% (26 wk) | ~14.9% (68 wk) | ~20.9% (72 wk) | ~2-3% |
| Combination weight loss | ~22.7% with sema (68 wk) | N/A | N/A | N/A |
| GI side effects | Moderate (nausea 32-45%) | Moderate (nausea 44%) | Moderate (nausea 31%) | High (nausea 28-48%) |
| Hypoglycemia risk | Very low (non-diabetic) | Very low | Very low | Low-moderate |
| Thyroid C-cell risk | No | Yes (label warning) | Yes (label warning) | No |
| Body composition | Favorable (70-75% fat) | Moderate | Favorable | Limited data |
| FDA approval status | Phase 3 (not yet approved) | Approved (Wegovy) | Approved (Zepbound) | Approved (Symlin) |
| Cost tier | Research-grade variable | High ($1,000+/mo) | High ($1,000+/mo) | Moderate |
| Route | SubQ injection | SubQ injection | SubQ injection | SubQ injection |
The comparison table reveals cagrilintide's key competitive position: it's not necessarily a replacement for semaglutide or tirzepatide in monotherapy (tirzepatide still leads for single-agent weight loss), but it occupies a unique combination partner role. The CagriSema combination's 22.7% weight loss in REDEFINE 1 currently represents the best-in-class result for any pharmacological obesity treatment without surgery.
For researchers specifically interested in the amylin pathway as distinct from incretin pharmacology, cagrilintide is the only viable long-acting option. Pramlintide's twice-daily dosing requirement and modest efficacy make it a poor substitute for research purposes.
What's Coming Next: The Pipeline and Open Questions
REDEFINE CVD: This cardiovascular outcomes trial will be the defining moment for CagriSema's regulatory trajectory. With semaglutide's SELECT trial demonstrating a 20% reduction in major adverse cardiovascular events (MACE), the expectation — and commercial pressure — is for CagriSema to match or exceed this benchmark. Given CagriSema's superior weight loss and metabolic marker improvements, the cardiovascular case looks promising, but outcomes data won't arrive until 2027-2028.
MASLD/NASH application: The hepatic fat reduction data from REDEFINE substudy (35% reduction in liver fat fraction) positions CagriSema as a potential treatment for metabolic-associated steatotic liver disease, now the fastest-growing indication in metabolic medicine. A dedicated MASLD phase 2 trial with cagrilintide/CagriSema is expected to be announced.
Cagrilintide + next-generation triple agonists: The obvious next research question is whether adding cagrilintide to triple agonists like retatrutide (GLP-1R/GIPR/GcgR) creates a quadruple-mechanism combination with further additive weight loss. Preclinical data suggests this is plausible, but the GI tolerability profile of such a combination is unknown.
Type 1 diabetes application: Amylin deficiency is a defining feature of type 1 diabetes (beta cells that produce amylin are destroyed along with insulin-producing cells). Pramlintide is already approved for this indication. Cagrilintide's once-weekly profile could dramatically improve adherence in T1D management. A dedicated T1D trial has not been announced but would be a logical development step.
Dose optimization above 4.5 mg: The phase 2 dose-response curve showed no plateau at 4.5 mg. Whether 6 mg, 9 mg, or higher doses of cagrilintide would produce further weight loss — and whether GI tolerability would limit dose escalation — is an open question. The REDEFINE 1 phase 3 used 2.4 mg cagrilintide in the combination, substantially below the maximum studied monotherapy dose, suggesting the combination field may not yet be optimized.
Mechanistic questions: The precise contribution of peripheral vs. central amylin receptor agonism to cagrilintide's weight loss effect hasn't been fully dissected in humans. Rodent studies suggest the brainstem area postrema is the dominant site, but selective peripheral vs. central administration studies in non-human primates show both compartments contribute meaningfully. Understanding this could guide next-generation formulation strategies.
Lean mass preservation with resistance training: No trial has yet examined whether structured resistance training during CagriSema treatment can preserve lean mass while maximizing fat loss — a critical practical question for the substantial population of active individuals using these agents.
🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.
Key Takeaways
Cagrilintide is a long-acting amylin analog: with a ~7-day half-life, enabling once-weekly subcutaneous dosing — a major practical advance over pramlintide's twice-daily requirement.
Mechanism is distinct from GLP-1 agonists: it acts primarily on AMY1 receptors in the area postrema and NTS, not GLP-1 receptors, making it genuinely complementary rather than redundant.
Monotherapy efficacy is substantial: 15.6% weight loss in 26 weeks at 4.5 mg, with the dose-response curve suggesting higher doses may produce further loss.
The CagriSema combination (2.4 mg cagrilintide + 2.4 mg semaglutide) achieved 22.7% weight loss: in REDEFINE 1 over 68 weeks — currently the best-in-class result for pharmacological obesity treatment.
57.4% of REDEFINE 1 participants achieved ≥20% weight loss: on CagriSema, a threshold previously associated only with bariatric surgery outcomes.
GI side effects are the primary tolerability concern: , with nausea in 28-45% at therapeutic doses, but managed effectively through dose escalation protocols.
Body composition is relatively favorable: approximately 70-75% of weight lost is fat mass, with less lean mass loss than might be expected from caloric restriction alone.
No thyroid C-cell risk from cagrilintide's amylin mechanism: (unlike GLP-1 receptor agonists), though this warning applies when used in CagriSema combination due to the semaglutide component.
Cardiovascular outcomes data (REDEFINE CVD) is the critical missing piece: for regulatory approval; results expected 2027-2028.
The amylin pathway represents a genuinely underexplored axis: of obesity pharmacology — cagrilintide's clinical success is likely to trigger broader interest in amylin receptor biology as a drug target.
Related Articles on BuyPeptidesOnline.com
Amycretin | Buy Online | Obesity Peptide Guide — The other dual amylin/GLP-1 approach in development
CagriSema Phase 3 Results | Weight Loss 2026 — Deep dive into REDEFINE 1 and 2 outcomes
Semaglutide Dosage Protocol Guide — Complete escalation guide for semaglutide, cagrilintide's combination partner
Best Weight Loss Peptides | Buy Online | Complete Guide — How cagrilintide ranks among all weight management peptides
Survodutide Weight Loss Results 2026 — Another next-generation obesity peptide with phase 3 data